Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants

Pediatric Infectious Disease Journal

Volumn 30, Issue 7, 2011, Pages 608-610

  Leuridan, Elke ^a   Hens, Niel ^a,b   Peeters, Natasja ^a   De Witte, Liene ^a   Van Der Meeren, Olivier ^c   Van Damme, Pierre ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

booster vaccination; maternal antibodies; neonatal pertussis

Indexed keywords

BACTERIAL ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; MATERNAL ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; INFANT; MULTICENTER STUDY; NEWBORN INFECTION; PASSIVE IMMUNIZATION; PERTUSSIS; PLACENTAL TRANSFER; PREPREGNANCY CARE; PRIORITY JOURNAL; PROGENY; SIBLING; UMBILICAL CORD BLOOD;

EID: 79959745852     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182093814     Document Type: Article

References (12)

1. Wendelboe AM, Van Rie A, Salmaso S, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005; 24(suppl 5):S58-S61. (Pubitemid 40676539)
2. Roehr B. Whooping cough outbreak hits several US states. BMJ. 2010;341: c4627.
3. Taranger J, Trollfors B, Lagergard T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis. 2000;181:1010-1013. (Pubitemid 30194485)
4. Healy CM, Munoz FM, Rench MA, et al. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis. 2004;190:335-340. (Pubitemid 38951975)
5. Murphy TV, Slade BA, Broder KR, et al. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-4):1-51.
6. Leuridan E, Hens N, Hutse V, et al. Early waning of maternal measles antibodies in the era of global measles vaccination. BMJ. 2010;340:c1626.
7. Greco D, Salmaso S, Mastrantonio P, et al. Progetto Pertosse Working Group. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996;334:341-348. (Pubitemid 26053148)
8. Blatter M, Friedland LR, Weston WM, et al. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine. 2009;27:765-772.
9. Storsaeter J, Hallander HO, Gustafsson L, et al. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16:1907-1916. (Pubitemid 28473934)
10. Tichmann I, Grunert D, Habash S, et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination. Hum Vaccin. 2006;2:249-254. (Pubitemid 46025656)
11. Wood N, McIntyre P, Marshall H, et al. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J. 2010;29:209-215.
12. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics. 1995;96(3 pt 2): 580-584.